More effective & durable treatments for cancer and immunological diseases
We aim to develop medicines that can positively transform patient lives
Stamford Pharmaceuticals Inc clinical trials
Who we are
We are a clinical stage oncology focused company developing novel gene therapies focused on dermatological and visceral cancers.
Our Approach
Cancers are complex dynamic and adaptive diseases with the tumor micro-environment comprising many different cell types, matrix proteins and secreted molecules.
The interplay between these elements impacts the responsiveness to therapy and whether there is continued tumor survival and progression, even in the face of continued treatments. We believe that remodelling of the tumor microenvironment and taking a multi-pathway and multi-target approach offers an opportunity to significantly improving response rates and durability of response.
Oncology Pipeline
Description
| Product – Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|
| SP-002 Platform | |||||
| SP-002: Phase 2/3 Basal Cell Carcinoma (BCC) – H/M-Zone |
Phase 2/3 |
Phase 2 studies completed. Commence Phase 2/3 in 2027 |
|||
| SP-002: Phase 1/2 Cutaneous SCC |
Phase 1/2 |
Open IND Phase 1/2 ready |
|||
| Vector-Drug Conjugate Platform | |||||
| SP-537 Pancreatic Cancer / H&N SCC |
Preclinical |
IND-enabling work ongoing | |||
| SP-563 Non-Muscle Invasive Bladder Cancer |
Preclinical |
IND-enabling work ongoing | |||
| SP-588 Organ Confined Prostate Cancer / DCIS-T1 Breast sCancer |
Preclinical |
IND-enabling work ongoing | |||
Our Disease Focus
H/M Zone nodular Basal Cell Carcinoma
Nodular Basal Cell Carcinomas in the H-zone.
Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC), is the second most common form of non-melanoma skin cancer (NMSC) comprising around 20% of all NMSC in the United States, with over 200,000 new cases each year.
News & Events
Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients January 17, 2025 Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT 04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5… Read more
Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects April 10, 2024 Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell… Read more
Stamford Expands its Scientific Advisory Team April 1, 2024 Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies, focused on cutaneous and visceral cancers, today announced that… Read more
- Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients January 17, 2025 Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT 04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5… Read more
- Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects April 10, 2024 Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell… Read more